Company recently announced definitive agreement to be acquired by AstraZeneca
FPI-2265 Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) expected to begin in Q2 2024
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Company recently announced definitive agreement to be acquired by AstraZeneca
FPI-2265 Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) expected to begin in Q2 2024
| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| FUSN | 21.55 | +0.03 | +0.14% |
| Fusion Pharmaceuticals Inc | |||